RICHARD G VINCENT
CIK 1269341 · Chief Financial Officer · last filed 2026-06-02
RICHARD G VINCENT is a Chief Financial Officer who has filed 29 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for FBRX, was dated Jun 2, 2026. Across all open-market trades the lifetime net is +$37.8K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
29
$37.8K
Holdings By Company
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-02 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-09-19 | FBRX | Grant (A) | — | $0 | EDGAR |
| 2024-02-15 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −8,868 | -$4.4K | EDGAR |
| 2023-10-04 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Mixed | — | $0 | EDGAR |
| 2023-07-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −7,069 | -$2.5K | EDGAR |
| 2023-04-14 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +30,000 | $9.0K | EDGAR |
| 2023-02-23 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −4,428 | -$4.5K | EDGAR |